Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tali Mazor

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2016
Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer SurvivorsAmy L Sherborne, Vincent Lavergne, Katharine Yu, et al.
Developmental Cell|April 23, 2021
Human placental cytotrophoblast epigenome dynamics over gestation and alterations in placental diseaseBo Zhang, M Yvonne Kim, GiNell Elliot, et al.
Neuro-Oncology|April 6, 2021
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomasYao Yu, Javier Villanueva-Meyer, Matthew R Grimmer, et al.
Cancer Cell|September 17, 2015
DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain TumorsTali Mazor, Aleksandr Pankov, Brett E Johnson, et al.
Acta Neuropathologica|March 1, 2015
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatmentHinke F van Thuijl, Tali Mazor, Brett E Johnson, et al.
NPJ Precision Oncology|October 6, 2022
MatchMiner: an open-source platform for cancer precision medicineHarry Klein, Tali Mazor, Ethan Siegel, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2017
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i>Tali Mazor, Charles Chesnelong, Aleksandr Pankov, et al.
Science (New York, N.Y.)|December 17, 2013
Mutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaBrett E Johnson, Tali Mazor, Chibo Hong, et al.
Nature Communications|July 11, 2024
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancerSuzanne J Forrest, Hersh Gupta, Abigail Ward, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2016
Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer SurvivorsAmy L Sherborne, Vincent Lavergne, Katharine Yu, et al.
Developmental Cell|April 23, 2021
Human placental cytotrophoblast epigenome dynamics over gestation and alterations in placental diseaseBo Zhang, M Yvonne Kim, GiNell Elliot, et al.
Neuro-Oncology|April 6, 2021
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomasYao Yu, Javier Villanueva-Meyer, Matthew R Grimmer, et al.
Cancer Cell|September 17, 2015
DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain TumorsTali Mazor, Aleksandr Pankov, Brett E Johnson, et al.
Acta Neuropathologica|March 1, 2015
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatmentHinke F van Thuijl, Tali Mazor, Brett E Johnson, et al.
NPJ Precision Oncology|October 6, 2022
MatchMiner: an open-source platform for cancer precision medicineHarry Klein, Tali Mazor, Ethan Siegel, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2017
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i>Tali Mazor, Charles Chesnelong, Aleksandr Pankov, et al.
Science (New York, N.Y.)|December 17, 2013
Mutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaBrett E Johnson, Tali Mazor, Chibo Hong, et al.
Nature Communications|July 11, 2024
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancerSuzanne J Forrest, Hersh Gupta, Abigail Ward, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Pageof 4